Printing the Future of Therapeutics in 3D
June 10-12, 2018
Vancouver, BC, Canada
Details on PFT3D 2018 coming soon!
2017 OPEN EVENTS
For PFT3D 2017, we held two events open to the public.
3D Bioprinting: Shaping the Future of Health
Imagine a world where drugs are developed without the use of animals, where doctors know how a patient will react to a drug before prescribing it and where patients can have a replacement organ 3D-printed using their own cells, without dealing with long donor waiting lists or organ rejection. 3D bioprinting could enable this world. Join us for lively discussion and dessert as experts in the field discuss the exciting potential of 3D bioprinting and the ethical issues raised when you can print human tissues on demand. This is also a rare opportunity to see a bioprinter live in action!
A Scientific Discussion on the Promise of 3D Bioprinting
The medical industry is struggling to keep our ageing population healthy. Developing effective and safe drugs is too expensive and time-consuming to continue unchanged. We cannot meet the current demand for transplant organs, and people are dying on the donor waiting list every day. We invite you to join an open session where four of the most influential academic and industry professionals in the field discuss how 3D bioprinting is being used to shape the future of health and what ethical challenges may be involved if you are able to print your own organs.
The University of British Columbia and the award-winning bioprinting company Aspect Biosystems, are proud to be co-organizing the second “Printing the Future of Therapeutics in 3D” International Research Roundtable. This event will once again congregate global leaders in tissue engineering research and pharmaceutical industry experts to discuss the rapidly emerging and potentially game-changing technology of 3D-printing living human tissues (bioprinting). The goals are to:
Highlight the state-of-the-art in 3D bioprinting research
Ideate on disruptive innovations that will transform bioprinting from a novel research tool to a broadly adopted systematic practice
Formulate an actionable strategy for industry engagement, clinical translation and societal impact
Present in a public forum, key messages to educate and stimulate discussion on the promises of bioprinting technology
The Roundtable will bring together a unique collection of industry experts and academic leaders to define a guiding vision to efficiently deploy bioprinting technology for the discovery and development of new therapeutics. As the novel technology of 3D bioprinting is more broadly adopted, we envision this Roundtable will become a key annual meeting to help guide the development of the technology both in Canada and globally.
We thank you for your involvement in this ground-breaking event and look forward to you all joining us in Vancouver for this unique research roundtable.
The Organizing Committee
Christian Naus, Professor, Cellular & Physiological Sciences, UBC
Vikram Yadav, Assistant Professor, Chemical & Biological Engineering, UBC
Tamer Mohamed, CEO, Aspect Biosystems
Sam Wadsworth, CSO, Aspect Biosystems
Natalie Korenic, Business Coordinator, Aspect Biosystems
Welcome and Overview
Preclinical Applications & Therapeutic Development
Commercialization & Industry Relevance
The Social Impact of Bioprinting
Scientist, Drug & Target Discovery
Founder & CEO
Project Mgmt and Collaborations, Immune-Oncology Translational Development
Arnold & Porter Kaye Scholer LLP
Department of Materials Science & Engineering, University of Toronto
The Providence Airway Centre (PAC) at the Centre for Heart Lung Innovation (HLI) at St. Paul’s Hospital
Over the three days, 24 influential innovators from around the world will discuss the latest technological advances and challenges of bioprinting living human tissues, including the technical, ethical and societal issues of how bioprinting could lead to a future where drugs are developed without the use of animals, and where customized replacement organs are fabricated on-demand, instead of donated.
9:00-3:25pm: Closed Session
5:30-8:00pm: Café Scientifique
8:00-10:00pm: Dinner at Science World
Click on each day above for fully detailed schedule
2017 VENUE & HOSTS
We are proud to be hosting this International Research Roundtable at the Peter Wall Institute for Advanced Studies on the beautiful University of British Columbia (UBC) campus in Vancouver, BC.
The Peter Wall Institute for Advanced Studies at the University of British Columbia (UBC) provides funding opportunities and an intellectual environment scholars are free to pursue the collaborative exchange of ideas beyond disciplinary boundaries.
The Institute’s goal is to stimulate creative, innovative research that makes important advances in knowledge, and to share or implement these ideas through ongoing community engagement. The Institute achieves this by supporting a highly collaborative environment at UBC where scholars have the opportunity to exchange ideas with national and international scholars, develop new thinking and engage in intellectual risk-taking.
The University of British Columbia is a global centre for research and teaching, consistently ranked among the 40 best universities in the world. Since 1915, UBC’s West Coast spirit has embraced innovation and challenged the status quo. Its entrepreneurial perspective encourages students, staff and faculty to challenge convention, lead discovery and explore new ways of learning. At UBC, bold thinking is given a place to develop into ideas that can change the world.
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.